RxDoctor Payments Data

Lisa Archer

Family · Centralia, WANPI 1043648702

Payments from drug & device makers

$786in general payments, 2019–2025

Across 36 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$277
  • AbbVie$163
  • Alkermes, Inc.$107
  • AstraZeneca$75
  • Exact Sciences$42
  • Pacira Pharmaceuticals Incorporated$25
  • plus $98 from 5 others

What the payments were for

  • Food & beverage$786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$786 in reported general payments places this provider in the 75th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$7,663
Medicare patients
54
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$121,167
JardianceEmpagliflozin65$59,320
EliquisApixaban48$39,640
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$28,998
JanuviaSitagliptin Phosphate17$21,770
TrulicityDulaglutide11$19,028
XareltoRivaroxaban14$14,973
OzempicSemaglutide15$13,942
BelsomraSuvorexant12$7,168
Advair HfaFluticasone Propion/Salmeterol13$6,076
SymbicortBudesonide/Formoterol Fumarate19$4,532
Levemir FlexpenInsulin Detemir19$3,790
Gabapentin117$3,252
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,246
Atorvastatin Calcium217$2,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$277$140,196102 claims
Johnson & JohnsonXarelto$25$14,97314 claims
Novo NordiskOzempic$18$13,94215 claims
AstraZenecaSymbicort$75$4,53219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,706 family providers in Washington.

Other family in Centralia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →